|Videos|October 14, 2022
Devon J. Shedlock, PhD, on Shifting from Autologous to Allogeneic Therapies
Author(s)Devon J. Shedlock, PhD
The chief scientific officer of cell therapy at Poseida Therapeutics discussed the company’s CAR-T and TCR technologies.
Advertisement
“We have developed an allogeneic CAR-T platform that we're expanding into TCRs. The nice thing about our platform is that because we're using the PiggyBac transposon technology, we’re able to have a larger CAR capacity. That easily enables the coexpression of a TCR along with a safety switch and a selection gene, with a CAR included as well.I think that's something that we can really leverage in our approach.”
Devon J. Shedlock, PhD, chief scientific officer, cell therapy, at Poseida Therapeutics, gave a presentation entitled “A Fully Allogeneic Tscm-based TCR-T Platform for Cncology & Beyond” on Poseida’s emerging technologies at the 7th Annual CAR-TCR Summit , held September 19-22, 2022, in Boston, Massachusetts.
Poseida Therapeutics is developing a pipeline of autologous and allogeneic chimeric antigen receptor (CAR) T-cell therapies for the treatment of both solid and liquid tumors, as well as rare diseases and hematological conditions. In his presentation, Shedlock discussed the company’s shift towards T-cell receptor (TCR) therapies and allogeneic therapies and the reasons behind this.
Shedlock discussed the Poseida’s TCR platform and its advantages in an interview with CGTLive. He touched on 2 of the company’s lead allogeneic programs right now, P-MUC1C-ALLO1 for solid tumors and P-BCMA-ALLO1 for multiple myeloma. He also shared his thoughts on why allogeneic CAR Ts are the future of the cell therapy space.
REFERENCE
Shedlock D. A fully allogeneic Tscm-based TCR-T platform for oncology & beyond. Presented at: 7th Annual CAR-TCR Summit. September 19-22, 2022; Boston, Massachusetts.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Related Articles
- Annaiz Grimm, BS, on Using EngTregs to Treat Autoimmune Disease
August 28th 2025
Advertisement
Advertisement
Trending on CGTlive®
1
Nanoscope Nabs RMAT Designation for Retinitis Pigmentosa Gene Therapy MCO-010
2
CGTLive®’s Weekly Rewind – September 5, 2025
3
Preclinical Evidence for PH1 Gene Therapy
4
Robert Alexander Wesselhoeft, PhD, on the Therapeutic Potential of Circular RNA
5